Literature DB >> 20513086

Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection.

Nuria Tormo1, Carlos Solano, Isabel Benet, José Nieto, Rafael de la Cámara, Ana Garcia-Noblejas, María Angeles Clari, Marifina Chilet, Javier López, Juan Carlos Hernández-Boluda, María José Remigia, David Navarro.   

Abstract

The dynamics of CMV pp65 and IE-1-specific IFNgamma-producing CD8(+) (IFNgamma CD8(+)) and CD4(+) (IFNgamma CD4(+)) T cells and CMV DNAemia were assessed in 19 pre-emptively treated episodes of active CMV infection. Peripheral counts of IFNgamma CD8(+) and IFNgamma CD4(+) T cells inversely correlated with CMV DNAemia levels (P = <0.001 and P = 0.003, respectively). A threshold value of 1.3 cells/microl predicting CMV DNAemia clearance was established for IFNgamma CD8(+) T cells (PPV, 100%; NPV, 93%) and for IFNgamma CD4(+) T cells (PPV, 100%; NPV, 75%). Undetectable T-cell responses were usually observed at the time of initiation of pre-emptive therapy. Either a rapid (within 7 days) or a delayed (median 31 days) expansion of both T-cell populations concomitant with CMV DNAemia clearance was observed in 5 and 8 episodes, respectively. An inconsistent or a lack of expansion of both T-cell subsets was related to a persistent CMV DNAemia. Robust and maintained CMV-specific T-cell responses after CMV DNAemia clearance and cessation of antiviral therapy were associated with a null incidence of relapsing infections at least during the following month. Data obtained in the present study may be helpful in the design of therapeutic strategies for the management of active CMV infections in the allo-SCT recipient. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20513086     DOI: 10.1002/jmv.21799

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  11 in total

Review 1.  The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Miriam Ciáurriz; Amaya Zabalza; Lorea Beloki; Cristina Mansilla; Estela Pérez-Valderrama; Mercedes Lachén; Eva Bandrés; Eduardo Olavarría; Natalia Ramírez
Journal:  Cell Mol Life Sci       Date:  2015-07-15       Impact factor: 9.261

2.  Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-specific CD8+ T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients.

Authors:  Estela Giménez; Carlos Solano; José Ramón Azanza; Paula Amat; David Navarro
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

3.  Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients.

Authors:  María Ángeles Clari; Beatriz Muñoz-Cobo; Carlos Solano; Isabel Benet; Elisa Costa; María José Remigia; Dayana Bravo; Paula Amat; David Navarro
Journal:  Clin Vaccine Immunol       Date:  2012-02-29

Review 4.  CMV-specific immune reconstitution following allogeneic stem cell transplantation.

Authors:  Emily Blyth; Barbara Withers; Leighton Clancy; David Gottlieb
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

5.  Induction of A. fumigatus-specific CD4-positive T cells in patients recovering from invasive aspergillosis.

Authors:  Hetty Jolink; Renate S Hagedoorn; Ellen L Lagendijk; Jan W Drijfhout; Jaap T van Dissel; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2014-04-18       Impact factor: 9.941

6.  Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation.

Authors:  Sylvia Borchers; Melanie Bremm; Thomas Lehrnbecher; Elke Dammann; Brigitte Pabst; Benno Wölk; Ruth Esser; Meral Yildiz; Matthias Eder; Michael Stadler; Peter Bader; Hans Martin; Andrea Jarisch; Gisbert Schneider; Thomas Klingebiel; Arnold Ganser; Eva M Weissinger; Ulrike Koehl
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

7.  Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients.

Authors:  David Navarro; Paula Amat; Rafael de la Cámara; Javier López; Lourdes Vázquez; David Serrano; José Nieto; Monserrat Rovira; José Luis Piñana; Estela Giménez; Carlos Solano
Journal:  Open Forum Infect Dis       Date:  2016-05-18       Impact factor: 3.835

8.  An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.

Authors:  Sascha Barabas; Theresa Spindler; Richard Kiener; Charlotte Tonar; Tamara Lugner; Julia Batzilla; Hanna Bendfeldt; Anne Rascle; Benedikt Asbach; Ralf Wagner; Ludwig Deml
Journal:  BMC Immunol       Date:  2017-03-07       Impact factor: 3.615

Review 9.  The CD4+ T Cell Response to Human Cytomegalovirus in Healthy and Immunocompromised People.

Authors:  Eleanor Y Lim; Sarah E Jackson; Mark R Wills
Journal:  Front Cell Infect Microbiol       Date:  2020-05-19       Impact factor: 5.293

10.  Mathematical Modeling of Within-Host, Untreated, Cytomegalovirus Infection Dynamics after Allogeneic Transplantation.

Authors:  Elizabeth R Duke; Florencia A T Boshier; Michael Boeckh; Joshua T Schiffer; E Fabian Cardozo-Ojeda
Journal:  Viruses       Date:  2021-11-16       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.